A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJ. R. Brown, AS Freedman, Stacey M. Fernandes et al.|Haematologica|2013Cited by 14